Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review
Poststroke cognitive impairment (PSCI) refers to any level of cognitive decline occurring after a stroke, ranging from mild to severe impairments, while PSCI with dementia describes a more severe form where the cognitive decline significantly affects daily functioning and meets the clinical criteria...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Stroke Research and Treatment |
| Online Access: | http://dx.doi.org/10.1155/srat/6893801 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849730167825498112 |
|---|---|
| author | Renju Ravi Saibal Das Tahir Hakami Prakash B. M. Libby Pushparajan |
| author_facet | Renju Ravi Saibal Das Tahir Hakami Prakash B. M. Libby Pushparajan |
| author_sort | Renju Ravi |
| collection | DOAJ |
| description | Poststroke cognitive impairment (PSCI) refers to any level of cognitive decline occurring after a stroke, ranging from mild to severe impairments, while PSCI with dementia describes a more severe form where the cognitive decline significantly affects daily functioning and meets the clinical criteria for dementia. PSCI occurs in more than half of individuals who have had a stroke. Despite its high prevalence, the pharmacotherapeutic options for PSCI are limited. Several pharmacotherapeutic options like cholinesterase inhibitors (e.g., donepezil, galantamine, and rivastigmine) and N-methyl-D-aspartate receptor antagonists (e.g., memantine) have shown potential in improving cognitive functions. However, their overall effectiveness remains inconsistent across different studies and patient populations. Newer drugs such as citicoline, cilostazol, and antidepressants have shown promise, but further research is needed to validate their efficacy and safety specifically for PSCI management. |
| format | Article |
| id | doaj-art-32e1ed5d342e42d180e9dfc521112ffa |
| institution | DOAJ |
| issn | 2042-0056 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stroke Research and Treatment |
| spelling | doaj-art-32e1ed5d342e42d180e9dfc521112ffa2025-08-20T03:08:57ZengWileyStroke Research and Treatment2042-00562025-01-01202510.1155/srat/6893801Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A ReviewRenju Ravi0Saibal Das1Tahir Hakami2Prakash B. M.3Libby Pushparajan4Department of Clinical PharmacologyIndian Council of Medical Research-Centre for Ageing and Mental HealthDepartment of Clinical PharmacologyDepartment of Clinical PharmacologyDepartment of NeurologyPoststroke cognitive impairment (PSCI) refers to any level of cognitive decline occurring after a stroke, ranging from mild to severe impairments, while PSCI with dementia describes a more severe form where the cognitive decline significantly affects daily functioning and meets the clinical criteria for dementia. PSCI occurs in more than half of individuals who have had a stroke. Despite its high prevalence, the pharmacotherapeutic options for PSCI are limited. Several pharmacotherapeutic options like cholinesterase inhibitors (e.g., donepezil, galantamine, and rivastigmine) and N-methyl-D-aspartate receptor antagonists (e.g., memantine) have shown potential in improving cognitive functions. However, their overall effectiveness remains inconsistent across different studies and patient populations. Newer drugs such as citicoline, cilostazol, and antidepressants have shown promise, but further research is needed to validate their efficacy and safety specifically for PSCI management.http://dx.doi.org/10.1155/srat/6893801 |
| spellingShingle | Renju Ravi Saibal Das Tahir Hakami Prakash B. M. Libby Pushparajan Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review Stroke Research and Treatment |
| title | Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review |
| title_full | Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review |
| title_fullStr | Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review |
| title_full_unstemmed | Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review |
| title_short | Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review |
| title_sort | pharmacotherapy for poststroke cognitive impairment and poststroke cognitive impairment with dementia a review |
| url | http://dx.doi.org/10.1155/srat/6893801 |
| work_keys_str_mv | AT renjuravi pharmacotherapyforpoststrokecognitiveimpairmentandpoststrokecognitiveimpairmentwithdementiaareview AT saibaldas pharmacotherapyforpoststrokecognitiveimpairmentandpoststrokecognitiveimpairmentwithdementiaareview AT tahirhakami pharmacotherapyforpoststrokecognitiveimpairmentandpoststrokecognitiveimpairmentwithdementiaareview AT prakashbm pharmacotherapyforpoststrokecognitiveimpairmentandpoststrokecognitiveimpairmentwithdementiaareview AT libbypushparajan pharmacotherapyforpoststrokecognitiveimpairmentandpoststrokecognitiveimpairmentwithdementiaareview |